Literature DB >> 1332926

Anti-elastin antibodies in patients with lung cancer.

J Gmiński1, J Mykała-Cieśla, M Machalski, M Drózdz.   

Abstract

The aim of this study was to investigate anti-elastin antibodies of the IgG and IgM types in sera of patients suffering from lung cancer, using the DOT immunobinding assay. We studied 96 pathological and 40 control sera. Anti-elastin antibodies were found to be present in 45% of patients with small cell lung cancer, 19% of subjects with adenocarcinoma and not-identified lung tumor and 15% of patients with squamous cell lung cancer. They circulated in 5% of control persons only. The highest values of their titers were observed in the advanced stages of disease. In 55% of anti-elastin antibody positive small cell lung cancer patients, antibodies were of the IgM type, suggesting the initial step of the autoimmunization to elastin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1332926     DOI: 10.1016/0165-2478(92)90049-t

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  3 in total

1.  Impact of elastin-derived VGVAPG peptide on bidirectional interaction between peroxisome proliferator-activated receptor gamma (Pparγ) and beta-galactosidase (β-Gal) expression in mouse cortical astrocytes in vitro.

Authors:  Konrad A Szychowski; Jan Gmiński
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-12-03       Impact factor: 3.000

2.  The VGVAPG Peptide Regulates the Production of Nitric Oxide Synthases and Reactive Oxygen Species in Mouse Astrocyte Cells In Vitro.

Authors:  Konrad A Szychowski; Jan Gmiński
Journal:  Neurochem Res       Date:  2019-02-13       Impact factor: 3.996

3.  Specific role of N-methyl-D-aspartate (NMDA) receptor in elastin-derived VGVAPG peptide-dependent calcium homeostasis in mouse cortical astrocytes in vitro.

Authors:  Konrad A Szychowski; Jan Gmiński
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.